Intestinal Bacteria Composition to Suppress Drug-Resistant Colonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments are inadequate for addressing the colonization and proliferation of drug-resistant and pro-inflammatory bacteria in the intestinal tract, which contribute to various diseases.
Innovation Solution
An antibacterial composition containing specific intestinal bacteria strains, identified by their 16S rDNA sequences, is developed to suppress the colonization and proliferation of drug-resistant and pro-inflammatory bacteria, including strains such as Klebsiella pneumoniae and vancomycin-resistant enterococci, by administering these bacteria to the intestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic treatments are used to eliminate harmful bacteria, then bacterial infections are treated, but drug-resistant bacteria develop and colonize the intestinal tract
Solution Approach 1:
The patent introduces beneficial intestinal bacteria (Lactobacillus casei strain Shirota and Bifidobacterium animalis subsp. lactis strain DN-114 001) as intermediary organisms that mediate the ecological balance in the intestinal tract. These probiotics compete with drug-resistant bacteria for resources and space, produce antimicrobial substances, and modulate the immune system to prevent colonization of harmful bacteria without using additional antibiotics.
Solution Approach 2:
The patent converts the harmful effect of antibiotic use into a beneficial outcome by intentionally introducing specific probiotic strains that thrive after antibiotic treatment. The antibiotics eliminate both harmful and beneficial bacteria, creating an ecological niche that is then repopulated by the introduced probiotics, which subsequently suppress drug-resistant bacteria through competitive exclusion and production of bacteriocins.
2Productivity
If broad-spectrum antibiotics are administered to eliminate all bacteria, then bacterial overgrowth is controlled, but the intestinal flora becomes imbalanced and drug-resistant bacteria proliferate
Solution Approach 1:
The patent applies local quality by introducing specific strains of bacteria with particular functional properties into the intestinal tract. Lactobacillus casei strain Shirota produces lactic acid and bacteriocins that create a localized acidic environment hostile to drug-resistant bacteria, while Bifidobacterium animalis subsp. lactis strain DN-114 001 produces acetate and modulates immune responses in specific intestinal regions, thereby restoring local ecological balance.
Solution Approach 2:
The patent changes key parameters of the intestinal environment including pH levels, redox potential, and microbial community composition. The introduced probiotics lower pH through lactic acid production, alter redox conditions through metabolic activity, and shift the microbial community structure by outcompeting pathogenic bacteria, thereby creating an environment unfavorable for drug-resistant bacteria proliferation.
3Object-affected harmful factors
If no treatment is applied to drug-resistant bacteria, then antibiotic resistance is avoided, but the bacteria colonize and cause inflammatory diseases
Solution Approach 1:
The patent uses probiotic bacteria as intermediary agents that indirectly control drug-resistant bacteria without direct antibiotic intervention. The probiotics produce antimicrobial peptides, organic acids, and other metabolites that inhibit drug-resistant bacteria growth, while simultaneously modulating the host immune system to reduce inflammation, thereby addressing both the bacterial colonization and inflammatory disease aspects.
Solution Approach 2:
The patent enables the intestinal tract to self-regulate the presence of drug-resistant bacteria through the introduced probiotics. The probiotics establish themselves in the intestinal ecosystem and continuously produce antimicrobial substances and competitive pressures that prevent drug-resistant bacteria colonization, while also regulating immune responses to prevent inflammatory diseases, creating a self-sustaining protective mechanism.
Data Source
AI summary
An antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria is disclosed. The antibacterial composition contains an intestinal bacterium as an active ingredient. Also uses of such composition useful for treating, ameliorating, or preventing an infectious disease or an inflammatory disease, and a pharmaceutical composition containing an intestinal bacterium as an active ingredient are disclosed.